PTPRC and neoplasm: In this model, we examined tumour-resident T and B cells, which were labelled through the in vivo administration of non-depleting fluorescent-tagged antibodies (CD3-AF488 for T cells, CD8a-PE for cytotoxic T cells, B220-AF647 for B cells).